Biopure Corporation (Cambridge, MA) has successfully defended a challenge at the European Patent Office to its European Patent entitled, "A Method for Chromatographic Removal of Prions.
KAG624) CARL RAUSCH, CEO of BIOPURE CORPORATION (BPUR), describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward.
Biopure Corporation (Cambridge, MA; 617-234-6826) announced that its investigational oxygen therapeutic, Hemopure (hemoglobin glutamer -- 250 (bovine)) has been shown to sustain myocardial tissue oxygenation and heart function during severe constriction of a coronary artery, according to results from a pharmacology study presented at the American Society of Anesthesiologists Annual Meeting this week in Dallas, Texas.
Among his many accomplishments, he was co-founder of Biopure Corporation where he obtained multiple FDA and EMEA trial authorizations, managed the successful completion of over 170 pre-clinical and clinical trials, and negotiated several industry partnerships on a global scale.
Biopure Corporation (Cambridge, MA; 617-234-6826) announced that its investigational hemoglobin-based oxygen therapeutic, Hemopure (hemoglobin glutamer - 250 (bovine)), has been shown to improve tissue oxygenation and prevent tissue damage in ischemic conditions relating to hemorrhagic shock, brain hypoxia and heart attack, according to results from pharmacology studies recently reported at the 27th Annual Meeting of the International Society on Oxygen Transport to Tissue (ISOTT) at Dartmouth College (Hanover, NH).
Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues.
